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Summary 
Dopamine (DA) is known as a primary regulator of prolactin 
secretion (PRL) and angiotensin II (Ang II) has been recognized 
as one brain inhibitory factor of this secretion. In this work, 
estrogen-primed or unprimed ovariectomized rats were submitted 
to the microinjection of saline or Ang II after previous 
microinjection of saline or of DA antagonist (haloperidol, sulpiride 
or SCH) both in the medial preoptic area (MPOA). Our study of 
these interactions has shown that 1) estrogen-induced PRL 
secretion is mediated by Ang II and DA actions in the MPOA, i.e. 
very high plasma PRL would be prevented by inhibitory action of 
Ang II, while very low levels would be prevented in part by 
stimulatory action of DA through D2  receptors, 2) the inhibitory 
action of Ang II depends on estrogen and is mediated in part by 
inhibitory action of DA through D1 receptors and in other part by 
inhibition of stimulatory action of DA through D2 receptors. 
 
Key words  
Prolactin • Medial preoptic area • Angiotensin II • Dopaminergic 
antagonists • Estrogen  
 
Corresponding author 
Celso Rodrigues Franci, Departamento de Fisiologia, Faculdade 
de Medicina de Ribeirão Preto, Universidade de São Paulo, Av. 
Bandeirantes, 3900 - Campus USP, 14049-900, Ribeirão Preto, 
SP, Brazil, Fax: +55-16-3633 0017, E-mail: crfranci@fmrp.usp.br 
 
Introduction 
 
 The control of prolactin (PRL) secretion depends 
on the balance between the action of releasing (PRF) and 
inhibiting (PIF) factors. Dopamine (DA) has been 
recognized as the primary regulator of PRL synthesis and 
release. However, other hypothalamic, systemic and local 
factors act as inhibitors and stimulators (Ben-Jonathan 
and Hnasko 2001, Freeman et al. 2000). These factors 
include gamma aminobutyric acid (Schally et al. 1977), 
neuropeptide Y (Rettori et al. 1990, Silveira and Franci 
1999), atrial natriuretic peptide (Franci et al. 1992, 
Samson et al. 1988), oxytocin (Samson et al. 1986) and 
angiotensin II (Ang II) (Franci et al. 1997, Steele et al. 
1981), among others.   
 The rostral group of neurons in A14 nucleus, a 
periventricular structure, is responsible for DA 
innervation of the medial preoptic area (MPOA). This 
suggests that the MPOA as part of the incerto-
hypothalamic dopamine system may have involvement in 
neuroendocrine mechanisms (Björhlund et al. 1975, Day 
et al. 1980, Lindvall et al. 1984). The periventricular 
preoptic area neurons project heavily to the arcuate 
nucleus and median eminence (Conrad and Pfaff 1975). 
Studies that used transection techniques showed the 
interaction between preoptic area and medial basal 
hypothalamus, which contains the PRL-regulating 
tuberoinfundibular dopaminergic (TIDA) neurons (Arai 
and Yamanouchi 1975, Carrer and Taleisnick 1970). 
Basal plasma PRL was higher in deafferentated rats that 
showed persistent estrus relative to the deafferentated and 
sham-deafferentated rats that showed regular cycle. This 
may indicate that preoptic area neurons participate in the 
tonic hypothalamic inhibition of basal PRL secretion or 
the deafferentation disinhibited PRL-releasing factor 
pathways (Jakubowski et al. 1988). Preoptic-anterior 
hypothalamic area neurons that facilitate PRL secretion 
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may either stimulate the secretion of some PRF or inhibit 
the secretion of some PIF into the hypophysial portal 
vasculature (Day et al. 1982). Tissue extracts from this 
area have been reported to exhibit PRF activity in vitro 
(Krulich et al. 1971). 
 Hormonal state of an intact female influences the 
DA activity in the MPOA (Matuszewich et al. 2000). 
Estrogen stimulates the PRL secretion when is implanted 
into the preoptic area (Pan and Gala 1985).  
 MPOA shows angiotensin II (Ang II)-stained 
cell bodies (Lind et al. 1985), angiotensinogen mRNA, 
immunoreactive angiotensinogen, angiotensin converting 
enzyme, immunoreactive angiotensin II, angiotensin II 
binding sites (Bunnemann et al. 1993) and AT1 receptors 
(Phillips et al. 1993). Intracerebroventricular micro-
injection of Ang II decreases (Myers and Steele 1991) 
while of specific antiserum against Ang II increases 
plasma PRL (Franci et al. 1997) in estrogen-primed 
ovariectomized rats. Intracerebroventricular micro-
injection of Ang II excites a large proportion of neurons 
in the preoptic-anterior hypothalamic area, increasing the 
neuronal discharge frequency (Gronan and York 1978) 
and facilitating the release of norepinephrine and DA 
(Quadri et al. 1991, Summers and Phillips 1983). 
Microinjection of Ang II into the MPOA decreased 
plasma PRL in estrogen-primed ovariectomized rats. This 
response was blocked by losartan, an AT1 receptor 
antagonist (Dornelles and Franci 1998a), but it was not 
altered by alpha- or beta-adrenergic antagonists 
(Dornelles and Franci 1998b). 
 Considering that: 1) Ang II and DA act on PRL 
secretion, 2) the influence of estrogen on Ang II and DA 
activity in the preoptic area, we aimed to verify in this 
work: a) if the Ang II action in the MPOA on PRL 
secretion would be mediated by D1 and/or D2 receptors as 
well, and b) if the presence or absence of estrogen would 
modify this putative interaction.  
 
Methods 
 
Animals 
 Adult female Wistar rats weighing 180-200 g 
were kept in a light- and temperature-controlled 
environment (lights on from 7:00 to 19:00 h, 22 ± 2 °C), 
with free access to water and food.  
 
Surgery and treatments  
 All rats were ovariectomized (OVX) and 14 days 
later a unilateral stainless-steel cannula was implanted 
into the MPOA at the following coordinates: AP = 2.2, 
L = ±0.8, V = –7.9 using a stereotaxic instrument (Kopf, 
USA). The guide cannula was fixed to the skull with two 
screws and dental cement (Simplex Dental, Brazil). A 
mandril was used to prevent obstruction of the cannula. 
Animals were returned to individual cages after surgery 
carried out under sodium thiopental anesthesia 
(50 mg/kg, i.p., Abbott Laboratories, USA). An antibiotic 
(veterinary pentabiotic, Wyeth Ayerst, USA, 0.2 ml/rat) 
was injected intramuscularly following the two surgeries. 
One week after stereotaxic surgery, the animals were 
subcutaneously injected with estradiol benzoate 
(25 µg/0.5 ml vegetable oil, Schering- Kenilworth, USA, 
BE group) or vehicle oil (0.5 ml, OV group) for 3 days. 
On day 3, 24 h before the experiment, the animals were 
anesthetized i.p. with 1 ml of tribromoethanol (Aldrich 
Chem., USA) 2.5 % in saline/100 g b.w. for insertion of 
the intra-atrial catheter (tubing with a 0.020 x 0.037 
diameter, Dow Corning, USA) through the jugular vein.  
 
Experimental procedures 
 On the day of the experiment, between 8:30 to 
9:00 h, an extension of polyethylene tubing (PE 50) filled 
with heparin solution (1:40) in 0.9 % NaCl was attached 
to the distal end of the jugular cannula. After 30 min, 
heparinized blood samples (0.8 ml) were collected from 
the external jugular vein at the following intervals:  
–20 (basal bleeding), 0, 10, 20, 30 and 60 min, while the 
animal was freely moving in the cage. The volume of all 
samples was replaced immediately after each bleeding 
with an equivalent volume of saline (0.15 M NaCl). 
Plasma was separated by centrifugation at 4 °C and 
stored at –20 °C until the time for PRL measurement. 
 Saline (0.15 M NaCl), Ang II (Sigma, USA), 
haloperidol (D1/D2 receptor antagonist, RBI, USA), 
sulpiride (D2 receptor antagonist, RBI) or SCH 23390 
(D1 receptor antagonist, RBI) solutions were injected in a 
volume of 1 µl during one minute with a Hamilton 
syringe connected by a polyethylene tubing (PE-10) and 
injecting needle filled with the solution to be injected. 
The injections into the MPOA were carried out 10 min 
(NaCl, haloperidol, sulpiride or SCH) and 20 min (NaCl 
or Ang II) after basal bleeding (–20 min). The doses used 
for microinjections of drugs were based on literary data: 
100 pmol of Ang II (Dornelles and Franci 1998a,b), 5 µg 
of haloperidol (Weiss and Ettenberg 1986), 10 µg of  
sulpiride (Morutto and Phillips 1997) and 10 µg of SCH 
23390 (Moses et al. 1995). A blood sample was 
withdrawn immediately after the second microinjection 
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(time zero). At the end of the experiment, the brains were 
removed and fixed in 10 % formalin for histological 
analysis to confirm the localization of the cannula in the 
MPOA through frozen sections. Only animals with the 
confirmation of cannula placement in the MPOA (near 
90 %) were included for hormonal measurement. The tips 
of the cannulas did reach the bearings of the MPOA in 
that region near median line as shown in schematic map 
(Fig. 1) adapted from Paxinos and Watson (1997). 
 
Radioimmunoassay (RIA) 
 RIA for the measurement of plasma PRL was 
performed using a kit from the National Hormonal and 
Peptide Program of the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDKD, USA). The 
lower detectable amount of PRL RP3 standard was 
0.2 ng/ml, the interassay coefficient of variation was 
11.7 %, and the intra-assay coefficient of variation was 
5.5 %. 
 
Statistical analysis  
 The data were analyzed statistically by analysis 
of variance for repeated measures, followed by Tukey's 
multiple range test using a computer software (SAS, 
USA). The level of significance was set at P<0.05. 
Results are expressed as means ± standard error.  
Results  
 
 The basal plasma PRL at –20 min was around 
10 ng/ml in the several unprimed ovariectomized groups 
 
 
Fig. 1. The gray area represents the site of cannulas tips
localization for microinjections in the preoptic area: ac – anterior 
commissure; ox – optic chiasm; MPA – medial preoptic area; 
MPOL –medial preoptic area, lateral part; Pe – periventricular
nucleus; AVPe – anteroventral periventricular nucleus. (Adapted 
from Paxinos and Watson (1997); bregma  –0.26 mm / interaural
8.74 mm). 
 
 
 
Fig. 2. Plasma PRL after following microinjections in the medial 
preoptic area (MPOA) of ovariectomized rats: NaCl +NaCl (Ο) 
and NaCl+ Ang II (●), panel 2.1; haloperidol +NaCl (Ο) and 
haloperidol + Ang II (●), panel 2.2; SCH +NaCl (Ο) and SCH + 
Ang II (●),panel 2.3; sulpiride +NaCl (Ο) and sulpiride + Ang II 
(●), panel 2.4; * P<0.05 vs NaCl + NaCl; # P<0.05 vs NaCl + Ang 
II. The number of animals in the groups was 10 to 14. 
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(Fig. 2) and 40 ng/ml in the several estrogen-primed 
ovariectomized groups (Fig. 3). The difference between 
unprimed ovariectomized groups and estrogen-primed 
ovariectomized groups was significant (p<0.001) and it 
indicates the known stimulatory action of estrogen on 
PRL secretion. 
 Microinjection of sulpiride (D2 receptor 
antagonist) in the MPOA decreased plasma PRL in 
estrogen-primed (F=22.987 for critical level of 2.353, 
Fig. 3.4) and unprimed (F=5.216 for critical level of 
2.331, Fig. 2.4) ovariectomized rats while microinjections 
of saline (Fig. 2.1 and 3.1), haloperidol (a D1/D2 receptor 
antagonist, Fig. 2.2 and 3.2) or SCH (D1 receptor 
antagonist, Fig. 2.3 and 3.3) in the MPOA did not change 
plasma PRL. The decrease of plasma PRL was significant 
at 30 and 60 min in estrogen-primed (Fig. 3.4) and at 20, 
30 and 60 min in unprimed ovariectomized rats (Fig. 2.4) 
that received sulpiride microinjection when compared 
with the control groups that received just microinjections 
of saline. 
 Figures 3.1 and 2.1 show that combined 
microinjections of Ang II with saline in the MPOA 
decreased the plasma PRL, respectively, in estrogen-
primed (F=213.67 for critical level of 2.315) and 
unprimed ovariectomized (F=5.216 for critical level of 
2.331) rats. This diminishing was significant at 10, 20, 30 
and 60 min in estrogen-primed (Fig. 3.1) and at 60 min in 
unprimed ovariectomized rats (Fig. 2.1) that received 
Ang II microinjection when compared with the respective 
control groups that received just microinjections of 
saline. 
 The combined microinjections of haloperidol 
(Fig. 2.2) or SCH (Fig. 2.3) with AngII in the MPOA did 
not change the plasma PRL in unprimed ovariectomized 
rats. However, plasma PRL decreased in the group that 
received the combined microinjections of sulpiride with 
Ang II (F=10.65 for critical level of 2.331, Fig. 2.4). This 
decrease was significant at 10 and 20 min in the group 
subjected to sulpiride microinjection combined with Ang 
II when compared with the group subjected to the 
microinjection of NaCl combined with Ang II (Fig. 2.1)  
 The combined microinjections of haloperidol 
with Ang II (Fig. 3.2) in the MPOA in estrogen-primed 
ovariectomized rats did not change plasma PRL. 
However, there was a change of plasma PRL in the group 
that received combined microinjections of sulpiride with 
AngII (F=97.744 for critical level of 2.315, Fig. 3.4) or 
SCH with Ang II (F=115.412 for critical level of 2.315, 
Fig. 3.3). Plasma PRL at 20, 30 and 60 min in the group 
submitted to the microinjection of sulpiride combined 
with Ang II (Fig. 3.4), at 30 and 60 min in the group, 
which had received a microinjection of SCH combined 
 
 
Fig. 3. Plasma PRL after following microinjections in the medial
preoptic area (MPOA) of estrogen-primed ovariectomized rats:
NaCl +NaCl (Ο) and NaCl+ Ang II (●), panel 3.1; haloperidol
+NaCl (Ο) and haloperidol + Ang II (●), panel 3.2; SCH +NaCl
(Ο) and SCH + Ang II (●), panel 3.3; sulpiride +NaCl (Ο) and 
sulpiride + Ang II (●), panel 3.4; * P<0.05 vs NaCl + NaCl;
# P<0.05 vs NaCl + Ang II. The number of animals in the groups
was 10 to 14. 
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with Ang II (Fig. 3.3) or at 10, 20, 30 and 60 min in the 
group received a microinjection of haloperidol combined 
with Ang II (Fig. 3.2) was significantly higher than in the 
group submitted to the microinjection of NaCl combined 
with Ang II (Fig. 3.1). 
 
Discussion 
 
 Our results (Figs 2.1 and 3.1) are in agreement 
with a known stimulatory action of estrogen on PRL 
secretion which involves: a) a direct effect on the 
pituitary to induce synthesis, storage and release of PRL 
(Maurer and Gorski 1977, Vician et al. 1979), 
b) stimulation and inhibition of hypothalamic releasing 
and inhibiting factors of PRL secretion, respectively 
(Demarest et al. 1984, Pilotte et al. 1984), and c) altered 
sensitivity of the pituitary to the regulating factors of 
PRL secretion (Raymond et al. 1978).  
 We observed a significant decrease in plasma 
PRL after microinjection of sulpiride (D2 receptor 
antagonist), but not of SCH (D1 receptor antagonist) or 
haloperidol (D1/D2 receptor antagonist) in the MPOA in 
estrogen-primed (Fig. 3) or unprimed (Fig. 2) 
ovariectomized rats. 
 The female hormonal state, the copulatory 
environment, and perineal stimulation modulate the 
activity of DA in the MPOA (Matuszewich et al. 2000). 
DA content (Crowley et al. 1978) and DA turnover 
(Wuttke et al. 1981) in the MPOA are lower in diestrus 
and proestrus than during estrus and metestrus. On the 
other hand, estrogen significantly reduces the DA 
turnover in the MPOA of ovariectomized rats (Hiemke et 
al. 1983). It has been suggested that the estrogen can 
block the DA neurotransmission in the MPOA at the 
postsynaptic level (Döcke et al. 1987).  
 How could the DA activity in the preoptic area 
influence the TIDA neurons that control the pituitary 
PRL secretion? PRL release involves two pathways, 
one originating from midbrain (ascending) and the other 
one from prefrontal cortex (descending), both projecting 
to the lateral and medial preoptic area. Then, the PRL 
release common pathway projects from the preoptic area 
caudally until the anterior hypothalamic area (Tindal and 
Knaggs 1972), which projects monosynaptically to the 
arcuate region (Kawakami and Sakuma 1976). Such a 
pathway would be well located to influence the system of 
DA neurons in the arcuate nucleus and hence to regulate 
the release of DA into the portal vessels. The stimulation 
of the rostral periventricular area might act by inhibiting 
transmission in dopaminergic neurons, which in turn, 
inhibit the release of DA from arcuate neurons and permit 
the release of PRL (Tindal and Knaggs 1972). 
Furthermore, the rostral periventricular region was found 
to be an effective site for stimulating prolactin release in 
the rat (Kawakami et al. 1973).  
 In situ hybridization studies indicate the 
presence of dopamine D1 and D2 receptors into the 
preoptic-anterior hypothalamic area (Tohyama and 
Takatsuji 1998). 
 Our results suggest a tonically active stimulation 
of PRL secretion by DA acting on D2 receptors in the 
MPOA via an estrogen-independent mechanism since the 
effect was observed in estrogen-primed and unprimed 
ovariectomized rats. However, we can not rule out a 
presynaptic D2 stimulatory autoreceptor regulation of 
endogenous DA release. In this case, the blockade of 
these receptors could induce an increase in DA 
endogenous that could act exclusively at postsynaptic D1 
receptors to inhibit the PRL release. The effect of 
haloperidol could be explained by its ability to block the 
presynaptic D2 stimulatory autoreceptors as well the pos-
synaptic effect through D1 receptors. On the basis of 
recent observations obtained with pharmacological 
probes more selective for different DA receptor subtypes, 
it was concluded that a simultaneous activation or 
inhibition of D1 and D2 receptors blocks the actions on 
TIDA neurons mediated by these receptors (Durham et 
al. 1998). Thus, it is possible that simultaneous blockade 
of D1/D2 receptors by haloperidol in the MPOA has also 
suppressed any action of DA on PRL secretion, while the 
blockade of only D2 receptors by sulpiride did block the 
tonically stimulated PRL secretion. 
 Ang II significantly decreased plasma PRL 
(Fig. 3.1) in estrogen-primed ovariectomized rats (from 
close to 40 ng/ml at –20 min to near 10 ng/ml at 60 min). 
This lower level was similar to that found in unprimed 
ovariectomized rats at –20 min (Fig. 2.1).  
 The endogenous angiotensin system in the 
preoptic-hypothalamic region does not seem to be 
involved in the maintenance of basal PRL secretion, since 
centrally administered Ang II receptor antagonists or 
angiotensin convertase inhibitors do not change PRL 
secretion in female or male rats (Dornelles and Franci 
1998a, Myers and Steele 1989, 1991). However, the 
blockade of the central Ang II system by these 
compounds greatly facilitates stress- or estradiol-induced 
PRL secretion (Myers and Steele 1989, 1991, Saavedra 
1992). Microinjection of Ang II into the MPOA 
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decreased plasma PRL in estrogen-primed 
ovariectomized rats. This response was blocked by 
losartan, an AT1 receptor antagonist (Dornelles and 
Franci 1998a), but it was not altered by alpha- or beta-
adrenergic antagonists (Dornelles and Franci 1998b). Our 
data suggest that Ang II may antagonize the stimulatory 
action of estrogen on PRL secretion and thereby to 
prevent hypersecretion of this hormone. Other 
investigators have also proposed a possible function of 
the angiotensin system in the hypothalamus to limit the 
magnitude of PRL secretion (Saavedra 1992, Steele 
1992).  
 There is colocalization of receptor mRNA, Ang 
II binding sites, Ang II immunoreactivity nerve terminals 
and Ang II receptors expression in the preoptic-
hypothalamic area (Lenkei et al. 1997), morover Ang II 
binding sites (Gomes et al. 2006) and AT1 receptors 
(Moreno and Franci 2005) colocalized in the MPOA. 
There is consistent evidence about the regulation of brain 
Ang II receptors by estrogen and progesterone as well the 
interaction of this regulation with brain areas related with 
the control of gonadotropin and PRL secretion. Arcuate 
nucleus from cycling rats on the estrus day or estrogen-
primed ovariectomized rats treated with progesterone 
presented an increased expression of AT1 receptors 
(Seltzer et al. 1993). AT1 receptors as well the expression 
of their mRNA are induced in the arcuate nucleus DA 
neurons of ovariectomized rats treated with estrogen and 
progesterone (Jöhren et al. 1997). Our group showed that 
Ang II receptors in the locus coeruleus, median preoptic 
nucleus and subfornical organ (Donadio et al. 2005) and 
ARC (Donadio et al. 2006) are upregulated in 
ovariectomized rats by treatment with estrogen and 
progesterone.  
 Is there any interaction between actions of Ang 
II and DA in the MPOA on PRL secretion? The 
microinjection of sulpiride or Ang II in the MPOA 
reduced PRL secretion in unprimed ovariectomized rats. 
However, the effect of sulpiride was observed earlier and 
persisted up to 60 min (Fig. 2.4), while the effect of Ang 
II was observed at 60 min (Fig. 2.1). Plasma PRL showed 
a similar profile in the group receiving the sulpiride/Ang 
II combination and the group receiving sulpiride/saline 
(Fig. 2.4). Thus, the effect of Ang II seems somehow to 
be masked by sulpiride. On the other hand, SCH 
(Fig. 2.3) and haloperidol (Fig. 2.2) blocked the effect of 
Ang II. Therefore, basal PRL secretion can be maintained 
in part by the stimulatory action of DA through D2 
receptors in unprimed ovariectomized rats, while the Ang 
II inhibitory action seems to depend on the action of DA 
mediated by D1 receptors, since SCH did block the effect 
of Ang II. 
 The inhibitory action of Ang II on PRL secretion 
in estrogen-primed ovariectomized rats was blocked by 
haloperidol, which acts through D1 and D2 receptors, and 
was partly reduced by sulpiride (D2 receptor antagonist) 
and SCH (D1 receptor antagonist). Thus, the blockade of 
both receptors did impede the Ang II inhibitory effect, 
while the blockade of either receptor type (D1 or D2) 
partly reduced the effect of Ang II. A previous study 
(Durham et al. 1998) showed that simultaneous activation 
or inhibition of D1 and D2 receptors blocked the actions 
on TIDA neurons mediated by these receptors. 
 Since PRL levels close to 40 ng/ml (at –20 min) 
decreased to near 25 ng/ml under the effect of sulpiride/ 
saline or of the sulpiride/Ang II combination in estrogen 
primed ovariectomized rats (Fig. 3.4), it seems that the 
effect of sulpiride masks the effect of Ang II also in this 
case, as was observed for unprimed ovariectomized rats.  
 Electrical stimulation of the MPOA decreased 
the magnitude of PRL surges in cycling rats during 
proestrous and estrous afternoon, in lactating rats during 
suckling as well in pregnant rats during day and night. 
These inhibitory mechanisms may be in the MPOA itself 
or another region whose projections continue through the 
MPOA (Wiersma and Kastelijn 1990). On the other hand, 
basal plasma levels of PRL decreased after 
microinjections of kainic acid in preoptic-anterior 
hypothalamic area (POA/AHA). The authors discovered 
that kainic acid caused extensive damage of medial 
region but not periventricular region of this area (Day et 
al. 1982). Studies of deafferentation of this area showed 
that POA neurons integrate some inhibitory tonic 
mechanism of basal PRL secretion (Jakubowski et al. 
1988). 
 The dual participation of neurons in the preoptic 
area to control PRL secretion is a puzzle with only few 
known pieces. Furthermore, there are no specific studies 
about the relationship between dopamine receptors in this 
brain area and PRL secretion control, estrogen levels or 
angiotensin II action in rat. Thus, the present work 
represents some contribution to the limited literature on 
this subject. 
 Taken together, our results raise some 
conclusions regarding the integration of mechanisms for 
the control of PRL secretion: 1) the estrogen stimulatory 
action is mediated in part by the stimulatory action of DA 
through D2 receptors and thus, the sulpiride should reduce 
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part of the estrogen effect on PRL secretion (Fig. 3), 
2) the inhibitory action of Ang II depends on estrogen 
and it is mediated in part by the inhibitory action of DA 
through D1 receptors and in other part by inhibition of the 
stimulatory action of DA through D2 receptors and so, the 
haloperidol should inhibit the effect of Ang II by 
blockade of both receptors, 3) plasma PRL induced by 
estrogen is mediated by Ang II and DA actions in the 
MPOA so that very high levels of plasma PRL should be 
prevented by the inhibitory action of Ang II, while very 
low levels should be impeded by the stimulatory action of 
DA through D2 receptors. 
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